Skip to main content
NCBI home page
Virologica Sinica logoLink to Virologica Sinica
. 2014 Sep 28;29(5):299–307. doi: 10.1007/s12250-014-3485-z

Three amino acid residues in the envelope of human immunodeficiency virus type 1 CRF07_BC regulate viral neutralization susceptibility to the human monoclonal neutralizing antibody IgG1b12

Jianhui Nie 1,2, Juan Zhao 2, Qingqing Chen 2, Weijin Huang 2, Youchun Wang 1,2,✉
PMCID: PMC8206421  PMID: 25273335

Abstract

The CD4 binding site (CD4bs) of envelope glycoprotein (Env) is an important conserved target for anti-human immunodeficiency virus type 1 (HIV-1) neutralizing antibodies. Neutralizing monoclonal antibodies IgG1 b12 (b12) could recognize conformational epitopes that overlap the CD4bs of Env. Different virus strains, even derived from the same individual, showed distinct neutralization susceptibility to b12. We examined the key amino acid residues affecting b12 neutralization susceptibility using single genome amplification and pseudovirus neutralization assay. Eleven amino acid residues were identified that affect the sensitivity of Env to b12. Through site-directed mutagenesis, an amino acid substitution at position 182 in the V2 region of Env was confirmed to play a key role in regulating the b12 neutralization susceptibility. The introduction of V182L to a resistant strain enhanced its sensitivity to b12 more than twofold. Correspondingly, the introduction of L182V to a sensitive strain reduced its sensitivity to b12 more than tenfold. Amino acid substitution at positions 267 and 346 could both enhance the sensitivity to b12 more than twofold. However, no additive effect was observed when the three site mutageneses were introduced into the same strain, and the sensitivity was equivalent to the single V182L mutation. CRF07_BC is a major circulating recombinant form of HIV-1 prevalent in China. Our data may provide important information for understanding the molecular mechanism regulating the neutralization susceptibility of CRF07_BC viruses to b12 and may be helpful for a vaccine design targeting the CD4bs epitopes.

Keywords: human immunodeficiency virus type 1, CRF07_BC, envelope glycoprotein, IgG1b12, neutralizing antibody, single genome amplification

References

  1. Balazs A B, Chen J, Hong C M, Rao D S, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 2012;481:81–84. doi: 10.1038/nature10660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barbas C F, 3rd, Bjorling E, Chiodi F, Dunlop N, Cababa D, Jones T M, Zebedee S L, Persson M A, Nara P L, Norrby E, et al. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci U S A. 1992;89:9339–9343. doi: 10.1073/pnas.89.19.9339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Binley J M, Wrin T, Korber B, Zwick M B, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petr-opoulos C J, Burton D R. Comprehensive crossclade neutralization analysis of a panel of anti-human imm-unodeficiency virus type 1 monoclonal antibodies. J Virol. 2004;78:13232–13252. doi: 10.1128/JVI.78.23.13232-13252.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Burton D R, Barbas C F, 3rd, Persson M A, Koenig S, Chanock R M, Lerner R A. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci U S A. 1991;88:10134–10137. doi: 10.1073/pnas.88.22.10134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Burton D R, Pyati J, Koduri R, Sharp S J, Thornton G B, Parren P W, Sawyer L S, Hendry R M, Dunlop N, Nara P L, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 1994;266:1024–1027. doi: 10.1126/science.7973652. [DOI] [PubMed] [Google Scholar]
  6. Butler D M, Pacold M E, Jordan P S, Richman D D, Smith D M. The efficiency of single genome amplification and sequencing is improved by quantitation and use of a bioinformatics tool. J Virol Methods. 2009;162:280–283. doi: 10.1016/j.jviromet.2009.08.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chong H, Hong K, Zhang C, Nie J, Song A, Kong W, Wang Y. Genetic and neutralization properties of HIV-1 env clones from subtype B/BC/AE infections in China. J Acquir Immune Defic Syndr. 2008;47:535–543. doi: 10.1097/QAI.0b013e3181663967. [DOI] [PubMed] [Google Scholar]
  8. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton R E, Hill C M, Davis C B, Peiper S C, Schall T J, Littman D R, Landau N R. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996;381:661–666. doi: 10.1038/381661a0. [DOI] [PubMed] [Google Scholar]
  9. Derdeyn C A, Decker J M, Sfakianos J N, Wu X, O’Brien W A, Ratner L, Kappes J C, Shaw G M, Hunter E. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol. 2000;74:8358–8367. doi: 10.1128/JVI.74.18.8358-8367.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Duenas-Decamp M J, Peters P, Burton D, Clapham P R. Natural resistance of human immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine residue close to the CD4 binding loop. J Virol. 2008;82:5807–5814. doi: 10.1128/JVI.02585-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gnanakaran S, Daniels M G, Bhattacharya T, Lapedes A S, Sethi A, Li M, Tang H, Greene K, Gao H, Haynes B F, Cohen M S, Shaw G M, Seaman M S, Kumar A, Gao F, Montefiori D C, Korber B. Genetic signatures in the envelope gly-coproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comput Biol. 2010;6:e1000955. doi: 10.1371/journal.pcbi.1000955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Haynes B F, Gilbert P B, McElrath M J, Zolla-Pazner S, Tomaras G D, Alam S M, Evans D T, Montefiori D C, Karnasuta C, Sutthent R, Liao H X, DeVico A L, Lewis G K, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb M L, Ngauy V, de Souza M S, Paris R, Ferrari G, Bailer R T, Soderberg K A, Andrews C, Berman P W, Frahm N, De Rosa S C, Alpert M D, Yates N L, Shen X, Koup R A, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael N L, Kim J H. Immunecorrelates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366:1275–1286. doi: 10.1056/NEJMoa1113425. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hessell A J, Poignard P, Hunter M, Hangartner L, Tehrani D M, Bleeker W K, Parren P W, Marx P A, Burton D R. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med. 2009;15:951–954. doi: 10.1038/nm.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kent S J, Cooper D A, Chhi Vun M, Shao Y, Zhang L, Ganguly N, Bela B, Tamashiro H, Ditangco R, Rerks-Ngarm S, Pitisuttithum P, Van Kinh N, Bernstein A, Osmanov S. AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccines. PLoS Med. 2010;7:e1000331. doi: 10.1371/journal.pmed.1000331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Li Y, Migueles S A, Welcher B, Svehla K, Phogat A, Louder M K, Wu X, Shaw G M, Connors M, Wyatt R T, Mascola J R. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med. 2007;13:1032–1034. doi: 10.1038/nm1624. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mo H, Stamatatos L, Ip J E, Barbas C F, Parren P W, Burton D R, Moore J P, Ho D D. Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off. J Virol. 1997;71:6869–6874. doi: 10.1128/jvi.71.9.6869-6874.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Moore J P, Cao Y, Leu J, Qin L, Korber B, Ho D D. Inter and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol. 1996;70:427–444. doi: 10.1128/jvi.70.1.427-444.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Nie J, Zhang C, Liu W, Wu X, Li F, Wang S, Liang F, Song A, Wang Y. Genotypic and phenotypic characterization of HIV-1 CRF01_AE env molecular clones from infections in China. J Acquir Immune Defic Syndr. 2010;53:440–450. doi: 10.1097/QAI.0b013e3181cb8300. [DOI] [PubMed] [Google Scholar]
  19. Palmer S, Kearney M, Maldarelli F, Halvas E K, Bixby C J, Bazmi H, Rock D, Falloon J, Davey R T, Jr., Dewar R L, Metcalf J A, Hammer S, Mellors J W, Coffin J M. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol. 2005;43:406–413. doi: 10.1128/JCM.43.1.406-413.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Pantophlet R, Ollmann Saphire E, Poignard P, Parren P W, Wilson I A, Burton D R. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol. 2003;77:642–658. doi: 10.1128/JVI.77.1.642-658.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Platt E J, Wehrly K, Kuhmann S E, Chesebro B, Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol. 1998;72:2855–2864. doi: 10.1128/jvi.72.4.2855-2864.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil J G, Francis D P, Stablein D, Birx D L, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb M L, Michael N L, Kunasol P, Kim J H, Investigators M-T. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209–2220. doi: 10.1056/NEJMoa0908492. [DOI] [PubMed] [Google Scholar]
  23. Roben P, Moore J P, Thali M, Sodroski J, Barbas C F, 3rd, Burton D R. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol. 1994;68:4821–4828. doi: 10.1128/jvi.68.8.4821-4828.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rolland M, Edlefsen P T, Larsen B B, Tovanabutra S, Sanders-Buell E, Hertz T, deCamp A C, Carrico C, Menis S, Magaret C A, Ahmed H, Juraska M, Chen L, Konopa P, Nariya S, Stoddard J N, Wong K, Zhao H, Deng W, Maust B S, Bose M, Howell S, Bates A, Lazzaro M, O’Sullivan A, Lei E, Bradfield A, Ibitamuno G, Assawadarachai V, O’Connell R J, deSouza M S, Nitayaphan S, Rerks-Ngarm S, Robb M L, McLellan J S, Georgiev I, Kwong P D, Carlson J M, Michael N L, Schief W R, Gilbert P B, Mullins J I, Kim J H. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature. 2012;490:417–420. doi: 10.1038/nature11519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Saphire E O, Parren P W, Pantophlet R, Zwick M B, Morris G M, Rudd P M, Dwek R A, Stanfield R L, Burton D R, Wilson I A. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science. 2001;293:1155–1159. doi: 10.1126/science.1061692. [DOI] [PubMed] [Google Scholar]
  26. Shang H, Han X, Shi X, Zuo T, Goldin M, Chen D, Han B, Sun W, Wu H, Wang X, Zhang L. Genetic and neutralization sensitivity of diverse HIV-1 env clones from chronically in-fected patients in China. J Biol Chem. 2011;286:14531–14541. doi: 10.1074/jbc.M111.224527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Teng T, Shao Y. Scientific approaches to AIDS pre-vention and control in China. Adv Dent Res. 2011;23:10–12. doi: 10.1177/0022034511398871. [DOI] [PubMed] [Google Scholar]
  28. Utachee P, Isarangkura-na-ayuthaya P, Tokunaga K, Ikuta K, Takeda N, Kameoka M. Impact of amino acid substitutions in the V2 and C2 regions of human im-munodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site. Retrovirology. 2014;11:32. doi: 10.1186/1742-4690-11-32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Utachee P, Nakamura S, Isarangkura-Na-Ayuthaya P, Tokunaga K, Sawanpanyalert P, Ikuta K, Auwanit W, Kameoka M. Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain. J Virol. 2010;84:4311–4320. doi: 10.1128/JVI.02619-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Veselinovic M, Neff C P, Mulder L R, Akkina R. Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model. Virology. 2012;432:505–510. doi: 10.1016/j.virol.2012.06.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Walker L M, Phogat S K, Chan-Hui P Y, Wagner D, Phung P, Goss J L, Wrin T, Simek M D, Fling S, Mitcham J L, Lehrman J K, Priddy F H, Olsen O A, Frey S M, Hammond P W, Kaminsky S, Zamb T, Moyle M, Koff W C, Poignard P, Burton D R. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009;326:285–289. doi: 10.1126/science.1178746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Walker L M, Huber M, Doores K J, Falkowska E, Pejchal R, Julien J P, Wang S K, Ramos A, Chan-Hui P Y, Moyle M, Mitcham J L, Hammond P W, Olsen O A, Phung P, Fling S, Wong C H, Phogat S, Wrin T, Simek M D, Koff W C, Wilson I A, Burton D R, Poignard P. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011;477:466–470. doi: 10.1038/nature10373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Wang S, Nie J, Wang Y. Comparisons of the genetic and neutralization properties of HIV-1 subtype C and CRF07/08_BC env molecular clones isolated from infections in China. Virus Res. 2011;155:137–146. doi: 10.1016/j.virusres.2010.09.012. [DOI] [PubMed] [Google Scholar]
  34. Wang Y, Li X, Song A, Zhang C, Chen Y, Chen C, Lin Y, Shun L, Li L, Liu Y, Yang J, Yang B, Tang Q, Harrison T J. Prevalence and partial sequence analysis of human T cell lymphotropic virus type I in China. J Med Virol. 2005;76:613–618. doi: 10.1002/jmv.20405. [DOI] [PubMed] [Google Scholar]
  35. Wei X, Decker J M, Liu H, Zhang Z, Arani R B, Kilby J M, Saag M S, Wu X, Shaw G M, Kappes J C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002;46:1896–1905. doi: 10.1128/AAC.46.6.1896-1905.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Wei X, Decker J M, Wang S, Hui H, Kappes J C, Wu X, Salazar-Gonzalez J F, Salazar M G, Kilby J M, Saag M S, Komarova N L, Nowak M A, Hahn B H, Kwong P D, Shaw G M. Antibody neutralization and escape by HIV-1. Nature. 2003;422:307–312. doi: 10.1038/nature01470. [DOI] [PubMed] [Google Scholar]
  37. Wu X, Yang Z Y, Li Y, Hogerkorp C M, Schief W R, Seaman M S, Zhou T, Schmidt S D, Wu L, Xu L, Longo N S, McKee K, O’Dell S, Louder M K, Wycuff D L, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong P D, Roederer M, Wyatt R T, Nabel G J, Mascola J R. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010;329:856–861. doi: 10.1126/science.1187659. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science. 1998;280:1884–1888. doi: 10.1126/science.280.5371.1884. [DOI] [PubMed] [Google Scholar]
  39. Zhang L, Chen Z, Cao Y, Yu J, Li G, Yu W, Yin N, Mei S, Li L, Balfe P, He T, Ba L, Zhang F, Lin H H, Yuen M F, Lai C L, Ho D D. Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china. J Virol. 2004;78:13591–13599. doi: 10.1128/JVI.78.24.13591-13599.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Zhang Y, Lu L, Ba L, Liu L, Yang L, Jia M, Wang H, Fang Q, Shi Y, Yan W, Chang G, Zhang L, Ho D D, Chen Z. Dominance of HIV-1 subtype CRF01_AE in sexually acquired cases leads to a new epidemic in Yunnan province of China. PLoS Med. 2006;3:e443. doi: 10.1371/journal.pmed.0030443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Zolla-Pazner S, deCamp A C, Cardozo T, Karasavvas N, Gottardo R, Williams C, Morris D E, Tomaras G, Rao M, Billings E, Berman P, Shen X, Andrews C, O’Connell R J, Ngauy V, Nitayaphan S, de Souza M, Korber B, Koup R, Bailer R T, Mascola J R, Pinter A, Montefiori D, Haynes B F, Robb M L, Rerks-Ngarm S, Michael N L, Gilbert P B, Kim J H. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One. 2013;8:e53629. doi: 10.1371/journal.pone.0053629. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Virologica Sinica are provided here courtesy of Wuhan Institute of Virology, Chinese Academy of Sciences

RESOURCES